Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 1 3

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Other solid neoplasm 2Gynecologic 2Thoracic 1Lymphoid 1

Conditions

Endometrial Neoplasms 2Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lung Neoplasms 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Appointments and Schedules × Clear all
NCT06628167 2026-03-24

LCS II

Abramson Cancer Center at Penn Medicine

Phase NA Completed
252 enrolled 7 charts
Thoracic

Lung Neoplasms

NCT06560632 2026-01-16

POLAR

Repare Therapeutics

Phase 1 Terminated
26 enrolled 14 charts
Other solid neoplasm

Advanced Solid Tumor

NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Juno Therapeutics, a Subsidiary of Celgene

Phase 1 Completed
387 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04763902 2023-11-30

TIMESPAN

University of Utah

Phase NA Completed
17 enrolled
Gynecologic

Endometrial Neoplasms

NCT04783467 2023-11-30

TREND

University of Utah

Phase NA Unknown
15 enrolled
Gynecologic

Endometrial Neoplasms

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

AbbVie

Phase 1 Completed
51 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡